Xenetic Biosciences, Inc.

Home
United States
Framingham, MA
Xenetic Biosciences, Inc.

XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Ltd.

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is

initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

04/27/2026

As concludes, Xenetic Biosciences continues working to advance innovative cancer therapies and improve patient outcomes.

Join the effort: https://bit.ly/4cbes1D

04/22/2026

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

https://bit.ly/4tpslkF

04/17/2026

Our proprietary platform continues to inspire hope by showing potential across a range of cancer indications and treatment approaches, targeting areas with critical unmet needs.

04/09/2026

Our mission is to redefine oncology treatments by advancing innovative therapies that target the tumor microenvironment.

04/06/2026

This , we’re focused on advancing science that supports better outcomes for patients affected by cancer.

Xenetic Biosciences remains committed to innovation in oncology.

03/27/2026

Pancreatic carcinoma remains one of the deadliest cancers. Each year in the U.S., roughly 67,000 people are diagnosed, and nearly 52,000 lives are lost.

We are dedicated to addressing this urgent unmet need.

03/20/2026

We are advancing our lead program toward the clinic, aiming to develop it as an adjunctive therapy for pancreatic carcinoma and other advanced .

Learn more: https://bit.ly/3PkEMfi

03/13/2026

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

https://bit.ly/4sawQ2f

03/12/2026

Our proprietary platform is designed to address critical unmet needs across multiple solid tumor indications.

At , we’re advancing innovative approaches with the potential to expand treatment possibilities and provide hope.

03/05/2026

Want to stay updated on our DNase technologies?
Stay in the loop by signing up for our alerts here: https://bit.ly/3zXgBLd

02/24/2026

At Xenetic Bio, we are focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers.

02/10/2026

Subscribe to our email alerts to stay informed about our latest news and events: https://bit.ly/3zXgBLd

Address

40 Speen Street
Framingham, MA
01701

Telephone

+17817787720

Website

http://www.xeneticbio.com/

Alerts

Be the first to know and let us send you an email when Xenetic Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xenetic Biosciences, Inc.:

Want your practice to be the top-listed Clinic in Framingham?

Our Story

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.